Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)

BACKGROUND: Lenalidomide has been approved for the treatment of lower-risk myelodysplastic syndrome (MDS) with 5q deletion (del(5q)). We present for the first time a retrospective analysis of low-risk MDS with isolated del5q treated with lenalidomide, outside the clinical trials. METHODS: 36 red blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Butrym, Aleksandra, Lech-Maranda, Ewa, Patkowska, Elżbieta, Kumiega, Beata, Bieniaszewska, Maria, Mital, Andrzej, Madry, Krzysztof, Torosian, Tigran, Wichary, Ryszard, Rybka, Justyna, Warzocha, Krzysztof, Mazur, Grzegorz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495845/
https://www.ncbi.nlm.nih.gov/pubmed/26152663
http://dx.doi.org/10.1186/s12885-015-1444-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495845/
https://www.ncbi.nlm.nih.gov/pubmed/26152663
http://dx.doi.org/10.1186/s12885-015-1444-1

Ejemplares similares